Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (3115)	12/3/1997 5:34:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Agouron Comments On Recent Decline In Stock Price - PRN more detail PR Newswire, Wednesday, December 03, 1997 at 15:27 LA JOLLA, Calif., Dec. 3 /PRNewswire/ -- Following the recent decline in Agouron Pharmaceuticals, Inc.'s (Nasdaq NNM: AGPH) shares, Peter Johnson, President and CEO issued the following statement: "We are shocked by the magnitude of the devaluation of AGPH shares in response to our decision to discontinue development of a cancer drug from which most analysts were expecting a contribution to our profitability of about 15 cents per share in the fiscal year 2000. It seems temporarily to have been forgotten that Agouron is the company that took control of a research compound from which a major pharmaceutical company had withdrawn financial support, successfully obtained FDA approval after completing one of the fastest development programs in the history of the US Pharmaceutical industry, and itself launched a drug in the US which after seven months has overtaken its three competitors to become the leader of its class in dollar market share, and appears to be on its way to generating greater first year sales than any other product from the biotech industry. Every successful research-based pharmaceutical company must have a first commercial product which stands alone until a second emerges. For more than ten years Agouron scientists have worked to assure that we will not remain a one product company. The breadth and diversification of Agouron's current portfolio of R&D programs is a powerful hedge against the inevitability that not every drug in research and development will succeed." Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company committed to discovery, development, manufacturing, and marketing of small- molecule drugs engineered to inactivate proteins which play key roles in cancer, AIDS, and other serious diseases. For further information about Agouron Pharmaceuticals, Inc., please see Agouron's web site at agouron.com SOURCE Agouron Pharmaceuticals, Inc.

To: Joe E. who wrote (3115)	12/3/1997 6:11:00 PM
From: Izzy	Respond to of 6136

Joe E.: Thank you for the excellent FDA url on PIs, which I think all should read carefully. A few comments: 1) Viracept should have been included as a PI demonstrating "reductions in both mortality and AIDS-defining clinical events" (I have asked AGPH to respond); 2) clearly Viracept has the most favorable adverse effect (side-effects) profile; 3) patients should not take Versed (commonly used sedative for diagnostic procedures, such as bronchoscopy/colonoscopy); Viracept appears to have the best profile for not having other drug interactions, esp the NNRTIs; 4) patients should be careful with oral contraceptives. Personally, I cannot medically justify prescribing any other PI except Viracept.